121 related articles for article (PubMed ID: 17130095)
1. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.
Iversen P; Johansson JE; Lodding P; Kylmälä T; Lundmo P; Klarskov P; Tammela TL; Tasdemir I; Morris T; Armstrong J;
Scand J Urol Nephrol; 2006; 40(6):441-52. PubMed ID: 17130095
[TBL] [Abstract][Full Text] [Related]
2. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns CF; Navani S; Armstrong J
Prostate Cancer Prostatic Dis; 2007; 10(1):87-93. PubMed ID: 17102802
[TBL] [Abstract][Full Text] [Related]
5. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns C; Borchers T; Morris T; Armstrong J;
Prostate Cancer Prostatic Dis; 2005; 8(2):194-200. PubMed ID: 15931272
[TBL] [Abstract][Full Text] [Related]
7. [Effect of bicalutamide 150 mg, after 3 years of median follow-up, in non-metastatic prostatic cancer].
Fourcade RO; Richaud P; Brune D; Colombel P; Sarramon JP; Fournier G; Colombeau P
Prog Urol; 2003 Jun; 13(3):430-9. PubMed ID: 12940195
[TBL] [Abstract][Full Text] [Related]
8. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
10. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
Thomsen FB; Brasso K; Christensen IJ; Johansson JE; Angelsen A; Tammela TL; Iversen P;
Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
[TBL] [Abstract][Full Text] [Related]
12. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
[TBL] [Abstract][Full Text] [Related]
13. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
Iversen P; Johansson JE; Lodding P; Lukkarinen O; Lundmo P; Klarskov P; Tammela TL; Tasdemir I; Morris T; Carroll K;
J Urol; 2004 Nov; 172(5 Pt 1):1871-6. PubMed ID: 15540741
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
Wirth MP; See WA; McLeod DG; Iversen P; Morris T; Carroll K;
J Urol; 2004 Nov; 172(5 Pt 1):1865-70. PubMed ID: 15540740
[TBL] [Abstract][Full Text] [Related]
16. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
17. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
[TBL] [Abstract][Full Text] [Related]
18. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
19. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
Usami M; Akaza H; Arai Y; Hirano Y; Kagawa S; Kanetake H; Naito S; Sumiyoshi Y; Takimoto Y; Terai A; Yoshida H; Ohashi Y
Prostate Cancer Prostatic Dis; 2007; 10(2):194-201. PubMed ID: 17199134
[TBL] [Abstract][Full Text] [Related]
20. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
Bedognetti D; Rubagotti A; Conti G; Francesca F; De Cobelli O; Canclini L; Gallucci M; Aragona F; Di Tonno P; Cortellini P; Martorana G; Lapini A; Boccardo F
Eur Urol; 2010 Feb; 57(2):238-45. PubMed ID: 19481335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
